Matching articles for "Alzheimer's disease"
Issue 1757 · June 22, 2026
Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia

Auvelity (Axsome), an extended-release fixed-dose combination of dextromethorphan and bupropion that was approved by the FDA for treatment of major depressive disorder in 2022, has now been approved for…

Med Lett Drugs Ther. 2026 Jun 22; 68(1757):98-100 doi:10.58347/tml.2026.1757b
Auvelity (Axsome), an extended-release fixed-dose combination of dextromethorphan and bupropion that was approved by the FDA for treatment of major depressive disorder in 2022, has now been approved for treatment of agitation associated with dementia due to Alzheimer's disease (AD). It is the second product to be approved in the US for this indication; the oral second-generation antipsychotic drug brexpiprazole (Rexulti) was approved in 2023.
Issue 1751 · March 30, 2026
Comparison Table: Amyloid Beta-Directed Antibodies for Alzheimer's Disease (online only)

View the Comparison Table: Amyloid Beta-Directed Antibodies for Alzheimer's Disease

Med Lett Drugs Ther. 2026 Mar 30; 68(1751):e59-60 doi:10.58347/tml.2026.1751d
View the Comparison Table: Amyloid Beta-Directed Antibodies for Alzheimer's Disease
Issue 1751 · March 30, 2026
Drugs for Dementia

Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline also occurs in other neurological conditions, such as Parkinson's disease, Lewy body dementia, vascular dementia, and…

Med Lett Drugs Ther. 2026 Mar 30; 68(1751):49-56 doi:10.58347/tml.2026.1751a
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline also occurs in other neurological conditions, such as Parkinson's disease, Lewy body dementia, vascular dementia, and frontotemporal dementia.
Issue 1751 · March 30, 2026
Comparison Table: Drugs for Alzheimer's Disease Dementia (online only)

View the Comparison Table: Drugs for Alzheimer's Disease Dementia

Med Lett Drugs Ther. 2026 Mar 30; 68(1751):e57-8 doi:10.58347/tml.2026.1751c
View the Comparison Table: Drugs for Alzheimer's Disease Dementia
Issue 1747 · February 2, 2026
Elecsys — A Second Blood Test for Alzheimer's Disease

Elecsys Phospho-Tau (181P) Plasma (Roche), a blood-based diagnostic test, has been cleared by the FDA to aid in the initial assessment of amyloid plaque pathology associated with Alzheimer's disease (AD) in…

Med Lett Drugs Ther. 2026 Feb 2; 68(1747):18-20 doi:10.58347/tml.2026.1747b
Elecsys Phospho-Tau (181P) Plasma (Roche), a blood-based diagnostic test, has been cleared by the FDA to aid in the initial assessment of amyloid plaque pathology associated with Alzheimer's disease (AD) in patients ≥55 years old with signs of cognitive decline. It is the second blood test for AD biomarkers to be cleared by the FDA; the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test was cleared in 2025 (see Table 1).
Issue 1741 · November 10, 2025 Free
In Brief: Updates for Lecanemab (Leqembi) for Alzheimer's Disease

The FDA has recommended additional MRI monitoring during initiation of treatment with the amyloid beta-directed monoclonal antibody lecanemab-irmb (Leqembi) and has approved a new subcutaneously injected…

Med Lett Drugs Ther. 2025 Nov 10; 67(1741):182-3 doi:10.58347/tml.2025.1741d
The FDA has recommended additional MRI monitoring during initiation of treatment with the amyloid beta-directed monoclonal antibody lecanemab-irmb (Leqembi) and has approved a new subcutaneously injected formulation of the drug (Leqembi Iqlik) for maintenance treatment of Alzheimer's disease.
Issue 1735 · August 18, 2025 Free
In Brief: A New Donanemab (Kisunla) Dosing Regimen for Alzheimer's Disease

The FDA has approved a new titration regimen for donanemab ( Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody indicated for treatment of Alzheimer's disease. The new regimen is intended to…

Med Lett Drugs Ther. 2025 Aug 18; 67(1735):134-5 doi:10.58347/tml.2025.1735d
The FDA has approved a new titration regimen for donanemab ( Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody indicated for treatment of Alzheimer's disease. The new regimen is intended to reduce the risk of serious amyloid-related imaging abnormalities (ARIA) associated with use of the drug.
Issue 1732 · July 7, 2025
A Blood Test for Alzheimer's Disease

The FDA has cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio (Fujirebio), a bloodbased diagnostic test, for early detection of amyloid plaque pathology associated with Alzheimer's disease (AD) in…

Med Lett Drugs Ther. 2025 Jul 7; 67(1732):109 doi:10.58347/tml.2025.1732b
The FDA has cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio (Fujirebio), a bloodbased diagnostic test, for early detection of amyloid plaque pathology associated with Alzheimer's disease (AD) in adults ≥50 years old who are showing signs and symptoms of the disease. The new assay is the first blood test for amyloid biomarkers to become commercially available in the US. The Lumipulse G β-Amyloid Ratio (1-42/1-40), which measures amyloid biomarkers in cerebrospinal fluid (CSF), was cleared by the FDA in 2022.
Issue 1726 · April 14, 2025
Benzgalantamine (Zunveyl) for Alzheimer's Disease

The FDA has approved Zunveyl (Alpha Cognition), a delayed-release formulation of the prodrug benzgalantamine, for treatment of mild to moderate dementia of Alzheimer's disease (AD). Immediate- and…

Med Lett Drugs Ther. 2025 Apr 14; 67(1726):59-60 doi:10.58347/tml.2025.1726b
The FDA has approved Zunveyl (Alpha Cognition), a delayed-release formulation of the prodrug benzgalantamine, for treatment of mild to moderate dementia of Alzheimer's disease (AD). Immediate- and extended-release formulations of the acetylcholinesterase inhibitor galantamine have been available in the US for years for treatment of AD.
Issue 1726 · April 14, 2025 Free
In Brief: Once-Monthly Lecanemab (Leqembi) for Alzheimer's Disease

The amyloid beta-directed monoclonal antibody lecanemab-irmb ( Leqembi – Eisai/Biogen) has now been approved by the FDA for once-monthly use for treatment of Alzheimer's disease (AD) in patients with mild…

Med Lett Drugs Ther. 2025 Apr 14; 67(1726):64 doi:10.58347/tml.2025.1726f
The amyloid beta-directed monoclonal antibody lecanemab-irmb ( Leqembi – Eisai/Biogen) has now been approved by the FDA for once-monthly use for treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia. It was previously approved only for administration once every 2 weeks. Now, lecanemab can be given every 4 weeks after an 18-month initiation phase of biweekly administration.
Issue 1709 · August 19, 2024
Donanemab (Kisunla) for Alzheimer's Disease

Donanemab-azbt ( Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody, has been approved by the FDA for treatment of Alzheimer's disease (AD). The label states that the drug should only be…

Med Lett Drugs Ther. 2024 Aug 19; 66(1709):129-31 doi:10.58347/tml.2024.1709a
Donanemab-azbt ( Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody, has been approved by the FDA for treatment of Alzheimer's disease (AD). The label states that the drug should only be started in patients with mild cognitive impairment (MCI) or mild dementia. Donanemab is the third IV amyloid beta-directed monoclonal antibody to be marketed in the US. Lecanemab ( Leqembi – Biogen/Eisai) was approved by the FDA in 2023 for the same indication as donanemab. Aducanumab ( Aduhelm – Lilly) was granted accelerated approval in 2021, but it was withdrawn from the market earlier this year for commercial reasons.
Issue 1708 · August 5, 2024 Free
Table: Amyloid-Directed Antibodies for Alzheimer's Disease (online only)

View the Table: Amyloid-Directed Antibodies for Alzheimer's Disease

Med Lett Drugs Ther. 2024 Aug 5; 66(1708):e1-2 doi:10.58347/tml.2024.1708e
View the Table: Amyloid-Directed Antibodies for Alzheimer's Disease
Issue 1688 · October 30, 2023
AD-Detect — A Blood Test for Alzheimer's Disease

AD-Detect (Quest), a blood test to evaluate Alzheimer's disease risk, is being marketed directly to consumers. It has not been cleared or approved by the FDA (laboratory-developed tests like this one currently…

Med Lett Drugs Ther. 2023 Oct 30; 65(1688):175-6 doi:10.58347/tml.2023.1688b
AD-Detect (Quest), a blood test to evaluate Alzheimer's disease risk, is being marketed directly to consumers. It has not been cleared or approved by the FDA (laboratory-developed tests like this one currently do not need FDA authorization to be marketed).
Issue 1683 · August 21, 2023
Lecanemab (Leqembi) Granted Full Approval for Early Alzheimer's Disease

Lecanemab-irmb ( Leqembi – Eisai/Biogen), the IV amyloid-directed monoclonal antibody that received accelerated approval from the FDA in January 2023 for treatment of early Alzheimer's disease, has now…

Med Lett Drugs Ther. 2023 Aug 21; 65(1683):129-30 doi:10.58347/tml.2023.1683a
Lecanemab-irmb ( Leqembi – Eisai/Biogen), the IV amyloid-directed monoclonal antibody that received accelerated approval from the FDA in January 2023 for treatment of early Alzheimer's disease, has now received full approval from the FDA based on a trial showing that it slowed cognitive and functional decline in patients with mild cognitive impairment (MCI) or mild Alzheimer's disease dementia and confirmed presence of brain amyloid. The IV amyloid-directed monoclonal antibody aducanumab (Aduhelm) has received only an accelerated FDA-approval for the same indication.
Issue 1679 · June 26, 2023
Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia

The FDA has approved the oral second-generation antipsychotic drug brexpiprazole ( Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated with dementia due to Alzheimer's disease (AD).…

Med Lett Drugs Ther. 2023 Jun 26; 65(1679):99-101 doi:10.58347/tml.2023.1679b
The FDA has approved the oral second-generation antipsychotic drug brexpiprazole ( Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated with dementia due to Alzheimer's disease (AD). Brexpiprazole is the first drug to be approved in the US for this indication. It is also approved for treatment of schizophrenia and as an adjunct to antidepressants for treatment of major depressive disorder.
Issue 1669 · February 6, 2023
Lecanemab (Leqembi) for Alzheimer's Disease

Lecanemab-irmb ( Leqembi – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The label states that treatment…

Med Lett Drugs Ther. 2023 Feb 6; 65(1669):17-8 doi:10.58347/tml.2023.1669a
Lecanemab-irmb ( Leqembi – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The label states that treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia, the population in which the drug was initiated in clinical trials. Lecanemab is the second IV amyloid-beta directed monoclonal antibody to be approved for this indication; aducanumab (Aduhelm) was approved in 2021 and has the same restrictions on treatment initiation.
Issue 1666 · December 26, 2022
Dextromethorphan/Bupropion (Auvelity) for Depression

The FDA has approved an extended-release fixed-dose combination of dextromethorphan and bupropion ( Auvelity – Axsome) for treatment of major depressive disorder (MDD) in adults.

Med Lett Drugs Ther. 2022 Dec 26; 64(1666):201-3
The FDA has approved an extended-release fixed-dose combination of dextromethorphan and bupropion ( Auvelity – Axsome) for treatment of major depressive disorder (MDD) in adults.
Issue 1662 · October 31, 2022
Phosphodiesterase-5 Inhibitors for Alzheimer's Disease?

A reader asked us to review use of the phosphodiesterase-5 (PDE5) inhibitor sildenafil for treatment of Alzheimer's disease (AD).

Med Lett Drugs Ther. 2022 Oct 31; 64(1662):174-5
A reader asked us to review use of the phosphodiesterase-5 (PDE5) inhibitor sildenafil for treatment of Alzheimer's disease (AD).
Issue 1657 · August 22, 2022
Comparison Table: Drugs for Alzheimer's Disease (online only)

View the Comparison Table: Drugs for Alzheimer's Disease

Med Lett Drugs Ther. 2022 Aug 22; 64(1657):e136-7
View the Comparison Table: Drugs for Alzheimer's Disease
Issue 1657 · August 22, 2022
Drugs for Cognitive Loss and Dementia

Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular…

Med Lett Drugs Ther. 2022 Aug 22; 64(1657):129-36
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
Issue 1656 · August 8, 2022
A Donepezil Patch (Adlarity) for Alzheimer's Disease (online only)

A once-weekly transdermal formulation of the acetylcholinesterase inhibitor donepezil ( Adlarity – Corium) has been approved by the FDA for treatment of mild, moderate, and severe Alzheimer's disease (AD)…

Med Lett Drugs Ther. 2022 Aug 8; 64(1656):e128-9
A once-weekly transdermal formulation of the acetylcholinesterase inhibitor donepezil ( Adlarity – Corium) has been approved by the FDA for treatment of mild, moderate, and severe Alzheimer's disease (AD) dementia. Donepezil is the second acetylcholinesterase inhibitor to become available in a transdermal formulation; transdermal rivastigmine (Exelon Patch) , which is applied once daily, has been available for years for the same indication. Donepezil is also available in oral formulations ( Aricept , and generics) for treatment of AD dementia.
Issue 1629 · July 26, 2021 Free
Addendum: Aducanumab (Aduhelm) for Alzheimer's Disease

In June 2021, the FDA approved the IV amyloid beta-directed monoclonal antibody aducanumab (Aduhelm) for treatment of Alzheimer’s disease. The approval did not restrict use of the drug to patients with mild…

Med Lett Drugs Ther. 2021 Jul 26; 63(1629):120
In June 2021, the FDA approved the IV amyloid beta-directed monoclonal antibody aducanumab (Aduhelm) for treatment of Alzheimer’s disease. The approval did not restrict use of the drug to patients with mild cognitive impairment or mild dementia, which was the population enrolled in the clinical trials. Now, Biogen, with the permission of the FDA, has made an addition to the labeling of the drug that says: Treatment with Aduhelm should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
Issue 1628 · July 12, 2021
Aducanumab (Aduhelm) for Alzheimer's Disease

Aducanumab-avwa ( Aduhelm – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The approval was based on the…

Med Lett Drugs Ther. 2021 Jul 12; 63(1628):105-6
Aducanumab-avwa ( Aduhelm – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The approval was based on the surrogate endpoint of reduction in amyloid beta plaques in the brain. The manufacturer is required to conduct an additional randomized controlled trial to establish that reducing amyloid beta plaques with aducanumab improves clinical outcomes in patients with Alzheimer's disease.
Issue 1530 · September 25, 2017
Drugs for Cognitive Loss and Dementia

Alzheimer's disease (AD) is the most common cause of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular…

Med Lett Drugs Ther. 2017 Sep 25; 59(1530):155-61
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
Issue 1530 · September 25, 2017
Comparison Table: Drugs for Alzheimer's Disease (online only)

View the Comparison Table: Drugs for Alzheimer's Disease

Med Lett Drugs Ther. 2017 Sep 25; 59(1530):e162-3
View the Comparison Table: Drugs for Alzheimer's Disease
Issue 1473 · July 20, 2015
Namzaric - A Combination of 2 Old Drugs for Alzheimer's Disease

The FDA has approved Namzaric (Forest), a fixed-dose combination of extended-release (ER) memantine (Namenda XR) , an NMDA-receptor antagonist, and donepezil ( Aricept , and generics), an acetylcholinesterase…

Med Lett Drugs Ther. 2015 Jul 20; 57(1473):105-6
The FDA has approved Namzaric (Forest), a fixed-dose combination of extended-release (ER) memantine (Namenda XR) , an NMDA-receptor antagonist, and donepezil ( Aricept , and generics), an acetylcholinesterase inhibitor, for treatment of moderate to severe Alzheimer's type dementia in patients previously stabilized on both drugs. The patent for Namenda has recently expired and generic formulations of memantine 5- and 10-mg tablets have been approved.
Issue 134 · October 1, 2013
Drugs for Cognitive Loss and Dementia

Alzheimer's disease (AD) is the most common cause of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, and vascular…

Treat Guidel Med Lett. 2013 Oct; 11(134):95-100
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, and vascular dementia. Mild cognitive impairment (MCI) is generally defined as cognitive decline greater than expected for an individual's age and educational level, but not interfering with activities of daily living; it may be a transitional state between the cognitive changes of normal aging and dementia.
Issue 1394 · July 9, 2012
An Imaging Agent for Amyloid

The FDA has approved florbetapir F18 (flor bay´ ta pir; Amyvid – Lilly), an intravenous radioactive diagnostic agent used with positron emission tomography (PET) scans, to estimate β-amyloid neuritic…

Med Lett Drugs Ther. 2012 Jul 9; 54(1394):54-5
The FDA has approved florbetapir F18 (flor bay´ ta pir; Amyvid – Lilly), an intravenous radioactive diagnostic agent used with positron emission tomography (PET) scans, to estimate β-amyloid neuritic plaque density in adults being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Issue 1366 · June 13, 2011
Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect

The FDA has approved Nuedexta (Avanir) , a fixed-dose combination of the cough suppressant dextromethorphan hydrobromide and the antiarrhythmic quinidine sulfate, for oral treatment of pseudobulbar affect. The…

Med Lett Drugs Ther. 2011 Jun 13; 53(1366):46-7
The FDA has approved Nuedexta (Avanir) , a fixed-dose combination of the cough suppressant dextromethorphan hydrobromide and the antiarrhythmic quinidine sulfate, for oral treatment of pseudobulbar affect. The combination is the first treatment approved by the FDA for this indication. Studies to support the effectiveness of Nuedexta were performed in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS); the drug has not been shown to be safe or effective in other types of emotional lability.
Issue 1347 · September 20, 2010 Free
Nonstandard Uses of Chelation Therapy

Chelation therapy involves oral administration, intravenous infusion or intramuscular injection of drugs that increase excretion of heavy metals. The Medical Letter’s last article on this subject found no…

Med Lett Drugs Ther. 2010 Sep 20; 52(1347):75-6
Chelation therapy involves oral administration, intravenous infusion or intramuscular injection of drugs that increase excretion of heavy metals. The Medical Letter’s last article on this subject found no evidence that it was effective for treatment of cardiovascular disease. Since then, off-label use of chelation therapy has expanded to include treating children with autism and adults with Alzheimer’s disease, cancer and other chronic diseases. Click here to view the free full article.
Issue 91 · March 1, 2010
Drugs for Cognitive Loss and Dementia

Alzheimer’s disease (AD) is the most common form of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson’s disease, dementia with Lewy bodies or vascular…

Treat Guidel Med Lett. 2010 Mar; 8(91):19-24
Alzheimer’s disease (AD) is the most common form of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson’s disease, dementia with Lewy bodies or vascular dementia. Mild cognitive impairment (MCI) has been defined as cognitive decline greater than expected for an individual’s age and educational level, but not interfering with activities of daily living; it may be a transitional state between the cognitive changes of normal aging and dementia.
Issue 1282 · March 24, 2008
A Rivastigmine Patch for Dementia

Cholinesterase inhibitors are now used routinely in patients with dementia. Rivastigmine transdermal system ( Exelon Patch - Novartis), a patch formulation of the cholinesterase inhibitor rivastigmine…

Med Lett Drugs Ther. 2008 Mar 24; 50(1282):21-2
Cholinesterase inhibitors are now used routinely in patients with dementia. Rivastigmine transdermal system ( Exelon Patch - Novartis), a patch formulation of the cholinesterase inhibitor rivastigmine tartrate, has been approved by the FDA for treatment of mild to moderate dementia associated with Alzheimer's or Parkinson's disease. An oral formulation of rivastigmine tartrate has been available in the US since 2000,2 but gastrointestinal adverse effects possibly related to rapidly rising serum concentrations have limited its use.
Issue 54 · February 1, 2007
Drugs for Cognitive Loss and Dementia

Alzheimer's disease (AD) is the most common form of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, or vascular…

Treat Guidel Med Lett. 2007 Feb; 5(54):9-14
Alzheimer's disease (AD) is the most common form of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, or vascular dementia. Mild cognitive impairment (MCI) has been defined as cognitive decline greater than expected for an individual's age and educational level, but not interfering with activities of daily living; it may be a transitional state between the cognitive changes of normal aging and the earliest stages of dementia.1 In longitudinal studies, the rate of progression from MCI to clinically diagnosable AD is 10-15% per year.
Issue 1208 · May 9, 2005
Dehydroepiandrosterone (DHEA)

Dehydroepiandrosterone (DHEA), an endogenous adrenal steroid, is marketed as a dietary supplement in the US. It is widely promoted to reverse the effects of aging (loss of muscle, memory and libido) and has…

Med Lett Drugs Ther. 2005 May 9; 47(1208):37-8
Dehydroepiandrosterone (DHEA), an endogenous adrenal steroid, is marketed as a dietary supplement in the US. It is widely promoted to reverse the effects of aging (loss of muscle, memory and libido) and has been used by athletes as a substitute for anabolic steroids. DHEA is banned by the International Olympic Committee, National Collegiate Athletic Association, National Football League and other sports organizations, but it was specifically exempted from becoming a controlled substance in the Anabolic Steroid Control Act of 2004.
Issue 1204 · March 14, 2005
Solifenacin and Darifenacin for Overactive Bladder

Solifenacin succinate ( VESIcare - Yamanouchi and GlaxoSmithKline) and darifenacin hydrobromide ( Enablex - Novartis) have been approved by the FDA for oral treatment of overactive bladder.

Med Lett Drugs Ther. 2005 Mar 14; 47(1204):23-4
Solifenacin succinate ( VESIcare - Yamanouchi and GlaxoSmithKline) and darifenacin hydrobromide ( Enablex - Novartis) have been approved by the FDA for oral treatment of overactive bladder.
Issue 1165 · September 15, 2003
Memantine for Alzheimer's Disease

Memantine hydrochloride, which has been used to treat dementia in Germany ( Axura Merz) since 1982, has become the latest word-of-mouth miracle drug for Alzheimer's disease in the US (G Kolata, NY Times, June…

Med Lett Drugs Ther. 2003 Sep 15; 45(1165):73-4
Memantine hydrochloride, which has been used to treat dementia in Germany ( Axura Merz) since 1982, has become the latest word-of-mouth miracle drug for Alzheimer's disease in the US (G Kolata, NY Times, June 15, 2003). Forest Laboratories has submitted a New Drug Application to the FDA for memantine. This review describes the standard treatment for Alzheimer's Disease, mechanism of action, clinical studies, adverse effects and dosage. Also included are sections on availability of the drug and how some people are obtaining memantine from abroad.
Issue 905 · September 17, 1993
Tacrine for Alzheimer's Disease

Tacrine hydrochloride ( Cognex - Parke-Davis), an acridinamine derivative, will soon be available for treatment of cognitive deficits associated with Alzheimer's disease.

Med Lett Drugs Ther. 1993 Sep 17; 35(905):87-8
Tacrine hydrochloride ( Cognex - Parke-Davis), an acridinamine derivative, will soon be available for treatment of cognitive deficits associated with Alzheimer's disease.